Pelvic Floor Physical Therapy to Reduce Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Jan 7, 2024
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The incidence of benign prostatic hyperplasia (BPH) in men significantly increases with age and is estimated to impact over 80% of men 70 to 80 years of age. HoLEP is one of many treatments for BPH and associated lower urinary tract symptoms (LUTS). Compared to other minimally invasive surgical techniques for the treatment of BPH, HoLEP has been found to have superior outcomes and is a prostate size-independent procedure with excellent durability, high efficacy, and low complication rates. However, transient stress urinary incontinence (SUI) following HoLEP may last for several months after...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Adult males who have lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) and considering/undergoing HoLEP for LUTS/BPH treatment at the University of California Irvine Medical Center.
- • Age \>= 18
- • English-speaker
- Exclusion Criteria:
- • Non-English speaker
- • Having an indwelling catheter preoperatively
- • Neurological disorders that might potentially affect muscle function
- • Neurogenic bladder
- • Lumbosacral spine pathology
- • Any condition that can interfere with pelvic muscle function per principal investigator's discretion
About University Of California, Irvine
The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Orange, California, United States
Patients applied
Trial Officials
Akhil Das, MD
Principal Investigator
University of California, Irvine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported